Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878389 | PMC |
| http://dx.doi.org/10.1136/bcr-2017-222004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alexidine and Pentamidine Fold Inside the Bowl-Shaped Cavity of p-Sulfonato-calix[4]arene.
Chemistry
January 2025
Institute of Physical Chemistry Polish Academy of Sciences: Polska Akademia Nauk Instytut Chemii Fizycznej, Department IX Photochemistry and Spectroscopy, Kasprzaka 44/52, 01-224, Warsaw, POLAND.
We report on the U-shaped folding of flexible guest molecules of medicinal interest upon their inclusion into macrocyclic cavity of p-sulfonato-calix[4]arene in aqueous media. Alexidine and pentamidine are FDA-approved drug compounds currently rediscovered as potent membrane-targeting antibiotic adjuvants helping restore antibiotic activity against multidrug resistant bacteria pathogens. We have adopted host-guest and crystal engineering approach to study these drugs with a view of potential supramolecular formulations and/or crystal forms.
View Article and Find Full Text PDFFirst-line glaucoma monotherapy medication patterns in Finland during 1995-2019 based on a population-based study.
PLoS One
January 2025
Faculty of Medicine and Health Technology, Department of Ophthalmology, Tampere University, Tampere, Finland.
Background: The long-term patterns in first-line glaucoma medication are not well established. Exploring these in longitudinal and population-based settings would provide information for the healthcare systems to plan glaucoma care accordingly.
Objective: To evaluate patterns in first-line glaucoma monotherapy in Finland during 1995-2019 based on nationwide survey and register data.
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFClinical applicability of 2023 International Pediatric Nephrology Association recommended limited therapeutic drug monitoring formulae to assess mycophenolic acid exposure.
Pediatr Nephrol
January 2025
University of Western Ontario, London, ON, Canada.
Background: The 2023 IPNA guidelines recommended a 12-h mycophenolic acid (MPA) area under the curve (AUC) estimation for managing pediatric nephrotic syndrome and MPA AUC > 50 mg * h/L for an optimal therapeutic response to mycophenolate mofetil (MMF). The IPNA guidelines endorsed two limited AUC formulae based on three-point MPA measurements to predict 12-h MPA AUC. The relative performance of these two limited AUC formulae has not been tested.
View Article and Find Full Text PDFSuppression of MCP-1, IFN-γ and IL-6 production of HNSCC by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival.
Front Immunol
January 2025
Department of Otorhinolaryngology, Head and Neck surgery, University Hospital Leipzig, Leipzig, Germany.
Background: Adding pembrolizumab, an anti-PD-1 antibody approved for treatment of head and neck squamous cell carcinoma (HNSCC) to neoadjuvant (induction-) chemotherapy utilizing docetaxel and cisplatin (TP) followed by radiotherapy may improve outcome in larynx organ-preservation (LOP) that is investigated in the European Larynx-Organ preservation Study (ELOS). As biomarkers for response to TP and pembrolizumab +TP are missing but may include cytokines, this work aims on determining cytokines potentially linked to outcome as prognostic markers sufficient to predict and/or monitor response to successful LOP.
Methods: Collagenase IV digests were generated from 47 histopathological confirmed HNSCC tumor samples and seeded in 96-well plates containing pembrolizumab, docetaxel, cisplatin either solely or in binary or ternary combination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!